163 related articles for article (PubMed ID: 30447918)
1. The prognostic value of the systemic inflammatory response in randomised clinical trials in cancer: A systematic review.
Dolan RD; Laird BJA; Horgan PG; McMillan DC
Crit Rev Oncol Hematol; 2018 Dec; 132():130-137. PubMed ID: 30447918
[TBL] [Abstract][Full Text] [Related]
2. The role of the systemic inflammatory response in predicting outcomes in patients with advanced inoperable cancer: Systematic review and meta-analysis.
Dolan RD; McSorley ST; Horgan PG; Laird B; McMillan DC
Crit Rev Oncol Hematol; 2017 Aug; 116():134-146. PubMed ID: 28693795
[TBL] [Abstract][Full Text] [Related]
3. The role of the systemic inflammatory response in predicting outcomes in patients with operable cancer: Systematic review and meta-analysis.
Dolan RD; Lim J; McSorley ST; Horgan PG; McMillan DC
Sci Rep; 2017 Dec; 7(1):16717. PubMed ID: 29196718
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of systemic inflammation-based markers in advanced pancreatic cancer.
Martin HL; Ohara K; Kiberu A; Van Hagen T; Davidson A; Khattak MA
Intern Med J; 2014 Jul; 44(7):676-82. PubMed ID: 24750233
[TBL] [Abstract][Full Text] [Related]
5. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer.
McMillan DC
Cancer Treat Rev; 2013 Aug; 39(5):534-40. PubMed ID: 22995477
[TBL] [Abstract][Full Text] [Related]
6. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study.
Proctor MJ; Morrison DS; Talwar D; Balmer SM; Fletcher CD; O'Reilly DS; Foulis AK; Horgan PG; McMillan DC
Eur J Cancer; 2011 Nov; 47(17):2633-41. PubMed ID: 21724383
[TBL] [Abstract][Full Text] [Related]
7. Are Markers of Systemic Inflammation Good Prognostic Indicators in Colorectal Cancer?
Rossi S; Basso M; Strippoli A; Schinzari G; D'Argento E; Larocca M; Cassano A; Barone C
Clin Colorectal Cancer; 2017 Dec; 16(4):264-274. PubMed ID: 28412137
[TBL] [Abstract][Full Text] [Related]
8. Systemic inflammation and survival of patients with prostate cancer: evidence from the Glasgow Inflammation Outcome Study.
Shafique K; Proctor MJ; McMillan DC; Qureshi K; Leung H; Morrison DS
Prostate Cancer Prostatic Dis; 2012 Jun; 15(2):195-201. PubMed ID: 22343838
[TBL] [Abstract][Full Text] [Related]
9. The relationship between the insulin-like growth factor-1 axis, weight loss, an inflammation-based score and survival in patients with inoperable non-small cell lung cancer.
Meek CL; Wallace AM; Forrest LM; McMillan DC
Clin Nutr; 2010 Apr; 29(2):206-9. PubMed ID: 19748165
[TBL] [Abstract][Full Text] [Related]
10. Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients.
Song A; Eo W; Lee S
World J Gastroenterol; 2015 Nov; 21(43):12410-20. PubMed ID: 26604648
[TBL] [Abstract][Full Text] [Related]
11. Clinical implications of systemic inflammatory response markers as independent prognostic factors for advanced pancreatic cancer.
Qi Q; Geng Y; Sun M; Wang P; Chen Z
Pancreatology; 2015; 15(2):145-50. PubMed ID: 25641673
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of the high-sensitivity modified Glasgow prognostic score in patients with resectable non-small cell lung cancer.
Osugi J; Muto S; Matsumura Y; Higuchi M; Suzuki H; Gotoh M
J Cancer Res Ther; 2016; 12(2):945-51. PubMed ID: 27461679
[TBL] [Abstract][Full Text] [Related]
13. Prognostic performance of inflammation-based prognostic indices in patients with resectable colorectal liver metastases.
Neal CP; Cairns V; Jones MJ; Masood MM; Nana GR; Mann CD; Garcea G; Dennison AR
Med Oncol; 2015 May; 32(5):144. PubMed ID: 25807934
[TBL] [Abstract][Full Text] [Related]
14. Inflammation and cancer: What a surgical oncologist should know.
Dupré A; Malik HZ
Eur J Surg Oncol; 2018 May; 44(5):566-570. PubMed ID: 29530345
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the prognostic value of inflammation-based pathologic and biochemical criteria in patients undergoing potentially curative resection for colorectal cancer.
Roxburgh CS; Salmond JM; Horgan PG; Oien KA; McMillan DC
Ann Surg; 2009 May; 249(5):788-93. PubMed ID: 19387324
[TBL] [Abstract][Full Text] [Related]
16. Colorectal Cancer, Systemic Inflammation, and Outcome: Staging the Tumor and Staging the Host.
Park JH; Watt DG; Roxburgh CS; Horgan PG; McMillan DC
Ann Surg; 2016 Feb; 263(2):326-36. PubMed ID: 25575264
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the Glasgow Prognostic Score (GPS) and the modified Glasgow Prognostic Score (mGPS) in evaluating the prognosis of patients with operable and inoperable non-small cell lung cancer.
Fan H; Shao ZY; Xiao YY; Xie ZH; Chen W; Xie H; Qin GY; Zhao NQ
J Cancer Res Clin Oncol; 2016 Jun; 142(6):1285-97. PubMed ID: 26864695
[TBL] [Abstract][Full Text] [Related]
18. Glasgow prognostic score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy.
Linton A; Pond G; Clarke S; Vardy J; Galsky M; Sonpavde G
Clin Genitourin Cancer; 2013 Dec; 11(4):423-30. PubMed ID: 23816526
[TBL] [Abstract][Full Text] [Related]
19. Appraisal of inflammation-based prognostic scores in patients with unresectable perihilar cholangiocarcinoma.
Okuno M; Ebata T; Yokoyama Y; Igami T; Sugawara G; Mizuno T; Yamaguchi J; Nagino M
J Hepatobiliary Pancreat Sci; 2016 Oct; 23(10):636-642. PubMed ID: 27474781
[TBL] [Abstract][Full Text] [Related]
20. The value of the systematic inflammation-based Glasgow Prognostic Score in patients with gastric cancer: a literature review.
Gao Y; Huang D
J Cancer Res Ther; 2014; 10(4):799-804. PubMed ID: 25579511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
